Wednesday, June 2, 2010

Vol. 16, No. 11

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 16, No. 11  June 1, 2010
(The next issue will be on June 14, 2010)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
None submitted for this issue.
__________________________________________________________
POSITIONS SOUGHT/AVAILABLE
The Karolinska Institutet (KI) and the Stockholm County Council (SLL) are initiating a series of long-range thematic programs where basic and clinical research are integrated in an effort to synergize translational research. These programs will provide excellent possibilities for junior investigators to build strong, innovative and strategic research environments. Within the framework of the new Cardiovascular Program, we are announcing grants for Young Investigators who are currently, or in the process of becoming, an independent group leader.
The applicant is expected to be at one of the following levels:
  • Senior post-doctoral fellow with the ambition to start an independent research group.
  • Assistant professor (forskarassistent) or similar with an independent research program.
More information about the open positions and the application process can be found:
http://cmm.ki.se/en/Global-navigation/News/The-Karolinska-Institutet-announces-Research-Grants-for-Young-Investigators/
____________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1jQ7zV8sza75SoUPtqW5WY_/

Appa RS, Theill C, Hansen L, Moss J, Behrens C, Nicolaisen EM, Klausen NK, and Christensen MS (2010) Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model. Thromb Haemost 104:
http://www.ncbi.nlm.nih.gov/pubmed/20508904

Arbesu I and Soria JM (2009) Update to Soria et al.'s "F7 gene and clotting factor VII levels" (2005): Genetic determinants of quantitative traits in thrombotic disease. Hum Biol 81:869-874.
http://www.ncbi.nlm.nih.gov/pubmed/20504203

Beyer R, Ingerslev J, and Sorensen B (2010) Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia
http://www.ncbi.nlm.nih.gov/pubmed/20491963

Fernandes N, Mosnier LO, Tonnu L, and Heeb MJ (2010) Zn2+-containing protein S inhibits extrinsic factor X activating complex independently of tissue factor pathway inhibitor (TFPI). J Thromb Haemost
http://www.ncbi.nlm.nih.gov/pubmed/20492471

Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, Natarajan V, Rehm C, Hadigan C, and Sereti I (2010) Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS
http://www.ncbi.nlm.nih.gov/pubmed/20505494

Hu Z, Rao B, Chen S, and Duanmu J (2010) Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer 10:235
http://www.ncbi.nlm.nih.gov/pubmed/20504328

Kerk N, Strozyk EA, Poppelmann B, and Schneider SW (2010) The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. J Invest Dermatol
http://www.ncbi.nlm.nih.gov/pubmed/20505748

Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, Latchman DS, Townsend P, Isenberg DA, Rahman A, and Giles IP (2010) Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol
http://www.ncbi.nlm.nih.gov/pubmed/20483743

Raturi A and Ruf W (2010) Effect of PDI chaperone activity inhibition on tissue factor activity. J Thromb Haemost
http://www.ncbi.nlm.nih.gov/pubmed/20492472

Soria JM, Almasy L, Souto JC, Sabaterlleal M, Fontcuberta J, and Blangero J (2009) The F7 gene and clotting factor VII levels: Dissection of a human quantitative trait locus. Hum Biol 81:853-867.
http://www.ncbi.nlm.nih.gov/pubmed/20504202

Spira J, Plyushch O, Zozulya N, Yatuv R, Dayan I, Bleicher A, Robinson M, and Baru M (2010) Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor V. Haemophilia
http://www.ncbi.nlm.nih.gov/pubmed/20491957
__________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

 
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________